Kyowa Hakko Bio Co. Ltd. (Kyowa Hakko Bio) and Kyowa Hakko USA Inc. (Kyowa) recently celebrated the grand opening of its expanded citicoline manufacturing facility.
The new facility is at the Kyowa Hakko Bio Yamaguchi Production Center in Hofu City, Japan. The company says the occasion “marks a significant milestone” in the company’s growth journey. Kyowa Hakko Bio President and CEO Yuki Kanzaki underscored the pivotal role of Cognizin in the company’s future success.
The expansion of citicoline manufacturing facility not only meets the growing demand for the product, but also “establishes a resilient global supply of network catering to pharmaceutical and health food manufacturers,” the company says. Kyowa is a subsidiary of Kirin Holdings Co. Ltd. (Kirin Holdings), and Kirin says it is excited to integrate citicoline into its upcoming product development initiatives, which solidifies its commitment to health and wellbeing.
Kanzaki highlighted the importance of Cognizin in her address during the opening celebration. She noted that the event was momentous for the company’s future growth and emphasized that, through the stable supply of citicoline, Kyowa Hakko Bio is continuing to contribute to improving cognitive health, focus and attention, as it addresses the essential aspects of overall wellbeing.
Kyowa Hakko Bio says it remains dedicated to utilizing its cutting-edge fermentation technology to become “a global specialty fermentation manufacturer” with numerous cost-competitive product pipelines and further enhancing its leadership in the industry.